New results suggest that a technique called hematopoietic stem-cell transplantation may be effective, and safer than previously thought.
The method: Chemotherapy is used to destroy a patient’s faulty immune system. Then stem cells from the patient’s blood and bone marrow are infused to help rebuild it. The approach is being used to treat relapsing remitting MS, where patients have spells without symptoms before succumbing to the illness again.
The news: The BBC says that 100 patients from America, the UK, Sweden, and Brazil were divided into groups given either the therapy or drugs. One stem-cell patient relapsed with MS inside a year, compared with 39 in the drug group. Members of the stem-cell group also found that their symptoms eased, whereas they got worse in those taking drugs.
Why it matters: MS affects an estimated 2.5 million people worldwide. Patient deaths previously suggested that the new $40,000 treatment was riskier than regular therapy. This study suggests that might not be the case.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Forget designer babies. Here’s how CRISPR is really changing lives
The gene-editing tool is being tested in people, and the first treatment could be approved this year.
More than 200 people have been treated with experimental CRISPR therapies
But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.
Three-parent baby technique could create babies at risk of severe disease
The approach was designed to prevent mitochondrial disease, but new evidence shows it might not work as planned.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.